The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England
Open accessAbstract
OBJECTIVE To inform national policy making on the use of the 13-valent pneumococcal vaccine among risk groups we estimated the increased risk of invasive pneumococcal disease (IPD) outcomes among clinical risk groups. Three years of post 7-valent pneumococcal conjugate vaccine (PCV7) data was included to investigate the herd protection effects. METHODS Over 22,000 IPD patients in England (March 2002-March 2009 - aged 2 and over) were linked to their hospitalisation records. The prevalence of risk factors in these patients was compared to the prevalence of risk factors in the general population. RESULTS There was an increased odds ratio (OR) for hospitalisation (OR 11.7 2-15 years; 7.6 16-64; 2.7 65+) and death (OR 2.4 2-15 years, 3.9 16-64, 1.2 65+) from IPD among risk group. The most important risk factors that predict IPD are chronic liver disease, immunosuppression, and chronic respiratory diseases. Herd protection effects due to introduction of the 7-valent vaccine were identical in both patient groups as shown by the similar decline in the proportion of IPD caused by PCV7 serotypes in risk and non-risk groups. CONCLUSIONS There is a marked increased risk of IPD among those with certain clinical conditions, suggesting potential benefit from a targeted vaccination approach. However, the indirect protection from conjugate vaccination of children suggests PCV vaccination of high-risk groups may not provide substantial additional benefit once herd immunity takes effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Protective Efficacy of Polyvalent Pneumococcal Polysaccharide Vaccine
Shapiro, E. D., Berg, A. T., Austrian, R., Schroeder, D., Parcells, V., Margolis, A., Adair, R. K., & Clemens, J. D. (1991) · New England Journal of Medicine · doi:10.1056/nejm199111213252101 · Cited by 1,051
Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations
Butler, J. C. (1993) · JAMA · doi:10.1001/jama.270.15.1826 · Cited by 671
Miller, E., Andrews, N. J., Waight, P. A., Slack, M. P., & George, R. C. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70090-1 · Cited by 643
Self-citationAsthma as a risk factor for invasive pneumococcal disease
Talbot, T. R., Hartert, T. V., Mitchel, E., Halasa, N. B., Arbogast, P. G., Poehling, K. A., Schaffner, W., Craig, A. S., & Griffin, M. R. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044113 · Cited by 395
A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults
French, N., Gordon, S. B., Mwalukomo, T., White, S. A., Mwafulirwa, G., Longwe, H., Mwaiponya, M., Zijlstra, E. E., Molyneux, M. E., & Gilks, C. F. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0903029 · Cited by 352
Harboe, Z. B., Thomsen, R. W., Riis, A., Valentiner-Branth, P., Christensen, J. J., Lambertsen, L., Krogfelt, K. A., Konradsen, H. B., & Benfield, T. L. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000081 · Cited by 309
Flasche, S., Van Hoek, A. J., Sheasby, E., Waight, P., Andrews, N., Sheppard, C., George, R., & Miller, E. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001017 · Cited by 277
Self-citationClonal and Capsular Types Decide Whether Pneumococci Will Act as a Primary or Opportunistic Pathogen
Sjostrom, K., Spindler, C., Ortqvist, A., Kalin, M., Sandgren, A., Kuhlmann-Berenzon, S., & Normark, B. H. (2006) · Clinical Infectious Diseases · doi:10.1086/499242 · Cited by 255
Vaccination against pandemic influenza A/H1N1v in England: A real-time economic evaluation
Baguelin, M., Hoek, A. J. V., Jit, M., Flasche, S., White, P. J., & Edmunds, W. J. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.01.002 · Cited by 182
Risk of invasive pneumococcal infections among working age adults with asthma
Klemets, P., Lyytikäinen, O., Ruutu, P., Ollgren, J. P., Kaijalainen, T., Leinonen, M., & Nuorti, J. P. (2010) · Thorax · doi:10.1136/thx.2009.132670 · Cited by 109
Cited by
Waight, P. A., Andrews, N. J., Ladhani, S. N., Sheppard, C. L., Slack, M. P. E., & Miller, E. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)70044-7 · Cited by 589
Self-citationRates of Pneumococcal Disease in Adults With Chronic Medical Conditions
Shea, K. M., Edelsberg, J., Weycker, D., Farkouh, R. A., Strutton, D. R., & Pelton, S. I. (2014) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofu024 · Cited by 276
Rudolf, I., Bakonyi, T., Šebesta, O., Mendel, J., Peško, J., Betášová, L., Blažejová, H., Venclíková, K., Straková, P., Nowotny, N., et al. (2014) · Eurosurveillance · doi:10.2807/1560-7917.es2014.19.31.20867 · Cited by 65
Ofori-Anyinam, O., Leroux-Roels, G., Drame, M., Aerssens, A., Maes, C., Amanullah, A., Schuind, A., Li, P., Jain, V. K., & Innis, B. L. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.09.012 · Cited by 31
Metadata
- Authors
- van Hoek, A. J., Andrews, N., Waight, P. A., Stowe, J., Gates, P., George, R., & Miller, E.
- Venue
- Journal of Infection
- Publisher
- Elsevier BV
- Published
- 2012-07
- Volume
- 65
- Issue
- 1
- Pages
- 17-24
- ISSN
- 0163-4453 (ISSN-L)
- OpenAlex
- W2042234402
- Cited by
- 253
- References
- 15
- FWCI
- 15.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. https://app.cochat.ai/papers/10.1016/j.jinf.2012.02.017
- The paper
- van Hoek, A. J., Andrews, N., Waight, P. A., Stowe, J., Gates, P., George, R., & Miller, E. (2012). The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. Journal of Infection. https://doi.org/10.1016/j.jinf.2012.02.017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.